吡啶并嘧啶类Wee1激酶衍生物的三维定量构效关系与分子对接

采用比较分子场分析方法(CoMFA)和比较分子相似性指数分析方法(CoMSIA)对一系列吡啶并嘧啶类衍生物进行了三维定量构效关系(3D-QSAR)研究，建立了CoMFA和CoMSIA两种模型. 所构建的最佳模型的交叉验证相关系数分别为0.707和0.645，非交叉验证系数分别是0.964和0.972，模型的一些外部验证表明两个模型合理、可靠，并具有良好的预报能力. 同时，用分子对接的方法分析了该类化合物与Wee1激酶结构的作用模式，结果进一步表明，在R1和R5取代基上引入正电性基团，R2为体积小的电负性基团，同时选择体积中等和强的推电子的R3但亲水性的X取代基，能有效改善这类化合物的抑制活性.

3D-QSAR and Docking Studies of Pyrido[2,3-d]pyrimidine Derivatives as Wee1 Inhibitors

In order to investigate the inhibiting mechanism and obtain some helpful information for de-signing functional inhibitors against Wee1, three-dimensional quantitative structure-activity relationship (3D-QSAR) and docking studies have been performed on 45 pyrido2,3-d] pyrim-idine derivatives acting as Wee1 inhibitors. Two optimal 3D-QSAR models with significant statistical quality and satisfactory predictive ability were established, including the CoMFA model (q²=0.707, R²=0.964) and CoMSIA model (q²=0.645, R²=0.972). The external val-idation indicated that both CoMFA and CoMSIA models were quite robust and had high predictive power with the predictive correlation coefficient values of 0.707 and 0.794, essen-tial parameter r²_m values of 0.792 and 0.826, the leave-one-out r²_m(LOO) values of 0.781 and 0.809, r²_m(overall) values of 0.787 and 0.810, respectively. Moreover, the appropriate binding orientations and conformations of these compounds interacting with Wee1 were revealed by the docking studies. Based on the CoMFA and CoMSIA contour maps and docking analyses, several key structural requirements of these compounds responsible for inhibitory activity were identified as follows: simultaneously introducing high electropositive groups to the sub-stituents R1 and R5 may increase the activity, the substituent R2 should be smaller bulky and higher electronegative, moderate-size and strong electron-withdrawing groups for the substituent R3 is advantageous to the activity, but the substituent X should be medium-size and hydrophilic. These theoretical results help to understand the action mechanism and design novel potential Wee1 inhibitors.